Trial Search Results

Insulin Resistance in Patients With Mood Disorder

Insulin resistance is known to be associated with mood disorders and cognitive difficulties. The purpose of this study is to treat depressed patients with rosiglitazone (also known as [AKA] Avandia), therefore improving glucose sensitivity, which in turn has the potential to affect mood and thinking. We, the researchers at Stanford University, are recruiting men and women who have been diagnosed with depression, and are willing to participate in this 3 month study. Participation involves neuropsychological testing, 2 blood draws called an oral glucose tolerance test (OGTT), which tests for glucose and insulin levels, and the medication, rosiglitazone. Participants are allowed to continue on their current psychiatric medication.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: rosiglitazone

Phase:

N/A

Eligibility


Inclusion Criteria:- Current depression

   - Insulin resistance

   - Current physician/psychiatrist care

   - Between the ages of 18-60

   - Willing to sign the Human Subjects Protection Consent Form

   - Willing to have blood sampling

Exclusion Criteria:- Diabetes

   - History of unstable heat disease

   - Uncontrolled hypertension

   - Extensive use of alcohol

   - Current use of street drugs

   - History of myocardial infarction

   - History of cerebrovascular disease

Ages Eligible for Study

18 Years - 60 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting